| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.68B | -0.7% | -45.2% |
| Cost of Revenue | $1.08B | -1.5% | -43.8% |
| R&D Expense | $47.0M | — | -65.7% |
| SG&A Expense | $255.0M | — | -30.9% |
| Interest Expense | $40.0M | — | -51.8% |
| Pre-tax Income | $181.0M | +374.2% | +142.2% |
| Income Tax | $31.0M | — | -73.9% |
| Net Income | $161.0M | +227.8% | +127.3% |
| EPS (Basic) | $0.39 | +230.0% | +127.7% |
| EPS (Diluted) | $0.39 | +230.0% | +127.7% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $710.0M | -0.7% | -59.7% |
| Accounts Receivable | $1.70B | +86.7% | -25.8% |
| Inventory | $1.21B | +3.2% | -46.1% |
| Current Assets | $5.64B | +1.2% | -12.7% |
| Total Assets | $21.45B | -0.6% | -40.4% |
| Current Liabilities | $2.10B |
| -54.6% |
| Long-term Debt | $3.13B | -0.1% | -41.2% |
| Total Liabilities | $7.21B | -3.5% | -43.3% |
| Stockholders' Equity | $14.04B | +0.9% | -38.5% |